Pfizer IncChange company Symbol lookupSelect an option...PFE Pfizer IncCMCO Columbus McKinnon CorpPPBI Pacific Premier Bancorp IncCAT Caterpillar IncJHI John Hancock Investors TrustSLGN Silgan Holdings IncGBX Greenbrier Companies IncGOOG Alphabet IncPUCKU Goal Acquisitions CorpPRGO Perrigo Company PLCGo
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
CMCO Columbus McKinnon Corp
PPBI Pacific Premier Bancorp Inc
CAT Caterpillar Inc
JHI John Hancock Investors Trust
SLGN Silgan Holdings Inc
GBX Greenbrier Companies Inc
GOOG Alphabet Inc
PUCKU Goal Acquisitions Corp
PRGO Perrigo Company PLC
Health Care : Pharmaceuticals | Large Cap Value
Company profilePfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q3 ending 09/2022) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q3 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced November 1, 2022 | $1.78 | Q3 Consensus of 15 analysts | $1.39 | Difference from consensus | 28.33% | Q4 Earnings will announce | (Unconfirmed) February 6, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
PFE's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.